Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 4/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27039411 | 0.76 | DDB1 (0.49) | ABL1DDB1CRBN | |
| SCHEMBL27039385 | 0.75 | PTPN2 (0.65) | PTPN1KMT2AABL1RIN1DDB1 | |
| Hydrochloric Acid SCHEMBL27040326 | 0.75 | DDB1 (0.48) | ABL1DDB1CRBN | |
| SCHEMBL25416997 | 0.71 | DDB1 (0.49) | MEN1KMT2ADDB1CRBN | |
| SCHEMBL25193821 | 0.69 | DDB1 (0.49) | MEN1KMT2ADDB1CRBN | |
| SCHEMBL30289168 | 0.68 | TDP1 (0.53) | MEN1KMT2ADDB1CRBNNAMPT | |
| SCHEMBL25415807 | 0.67 | DDB1 (0.47) | DDB1CRBN | |
| SCHEMBL25190616 | 0.67 | DDB1 (0.47) | DDB1CRBN | |
| SCHEMBL27039585 | 0.67 | HPGD (0.42) | — | |
| SCHEMBL25504703 | 0.66 | DDB1 (0.45) | MEN1KMT2ADDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109881-A1 | Heteroaryl Compounds as Ligand Directed Degraders of IRAK4 | IRAK4, IRAK2, IRAK3 | PTPN1 575/4885RXRA 1082/4885RXRB 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.